Tirofiban hydrochloride monohydrate

• CAT Number: I001875
• CAS Number: 150915-40-5
• Molecular Formula: C22H39ClN2O6S
• Molecular Weight: 495.072
• Purity: ≥95%
• Synonyms: Tirofiban hydrochloride;Tirofiban;L 700462, MK 383, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine
• Target: Integrin
• Solubility: 10 mM in DMSO
• Storage: desiccated
• IUPAC Name: (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid;hydrate;hydrochloride
• InChI: InChI=1S/C22H36N2O5S.ClH.H2O/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18;;/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26);1H;1H2/t21-;;/m0../s1
• InChIKey: HWAAPJPFZPHHBC-FGJQBABTSA-N
• SMILES: CCCCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O.O.Cl

Tirofiban hydrochloride monohydrate (CAT: I001875) is a glycoprotein IIb/IIIa inhibitor that selectively blocks platelet glycoprotein IIb/IIIa receptors, thereby preventing platelet aggregation and clot formation. It is used in the management of acute coronary syndromes, such as unstable angina and non-ST-segment elevation myocardial infarction, and during percutaneous coronary intervention (PCI) procedures. Tirofiban hydrochloride monohydrate improves blood flow, maintains open blood vessels, and reduces the risk of ischemic events.

Reference

[1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46.
[2]. van /’t Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100.
[3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49.
[4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19.
[5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.